Trials / Completed
CompletedNCT02718898
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 149 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixekizumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2017-02-22
- Completion
- 2018-02-21
- First posted
- 2016-03-24
- Last updated
- 2019-09-16
- Results posted
- 2018-03-23
Locations
34 sites across 8 countries: United States, Australia, Austria, Belgium, Canada, Netherlands, Puerto Rico, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT02718898. Inclusion in this directory is not an endorsement.